Hancock Jaffe Laboratories IncのROCE

Hancock Jaffe Laboratories IncのROCEは何ですか。

Hancock Jaffe Laboratories IncのROCEは-27.53%です。

ROCEの定義は何ですか。



使用資本利益率(ROCE)は、企業の収益性とその資本が使用される効率を測定する財務比率です。

Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.

ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.

Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.

NASDAQのセクタHealth CareにおけるROCEの企業と比べるHancock Jaffe Laboratories Inc

Hancock Jaffe Laboratories Incは何をしますか。

Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.

Hancock Jaffe Laboratories Incと類似のroce